Hikma Pharmaceuticals Share News (HIK)

BUZZ-European pharma: top fallers on Stoxx 600 amid pricing pressure concern

** Hikma Pharmaceuticals, Shire, Qiagen , BB Biotech fall 3-5 pct ** Track weakness overnight in US healthcare, dragged down by >5% drop in Mylan as political pressure mounted on company after price increases for its EpiPen allergy treatment ** Democratic presidential candidate Hillar

Broker tips: Hikma, Drax, TT Electronics

(ShareCast News) - Hikma Pharmaceuticals' shares have been maintain as 'hold' by Numis, with a target price of 2660p, following the company's surprise profit warning earlier in August and its interim numbers out on Wednesday. In the six months to end-June, Hikma's core revenue rose to $882m, from $7

Hikma Pharmaceuticals maintained as 'Hold' by Numis with 2660p price target

(ShareCast News) - Hikma Pharmaceuticals' shares have been maintain as 'Hold' by Numis, with a target price of 2660p, following the company's surprise profit warning earlier in August and its interim numbers out on Wednesday. In the six months to end-June, Hikma's core revenue rose to $882m, from $7

CORRECT: Hikma Keeps 2016 Guidance, Interim Dividend As Profit Down

Hikma H1 operating profit drops but FY revenue guidance reiterated

(ShareCast News) - Hikma Pharmaceuticals reported a jump in first-half revenues but a drop in operating profit, as it reiterated its full-year revenue guidance. In the six months to the end of June, core revenue rose to $882m from $709m, but operating profit slipped to $176m from $204m due to a lowe

FTSE 100 movers: Housebuilders lead equities higher

(ShareCast News) - The FTSE 100 rose 0.66% to 6,873.69 points in afternoon trade on Tuesday, with housebuilders topping the London index. Persimmon led housebuilders higher after reporting a better-than-expected jump in first half profits. Pre-tax profit rose 29% to £352.3m in the six months to 30 J

Wednesday preview: Hikma Pharmaceuticals reports interims in wake of profit warning

(ShareCast News) - Hikma Pharmaceuticals reports its interim results on Wednesday just weeks after surprising the market with a profit warning. In a first half trading update on 4 August, the drug maker said it expected core operating profit of its generics arm to be between $30m and $40m, compared

UK Earnings, Trading Statements Calendar - Next 7 Days

LONDON MARKET CLOSE: Stocks Extend Rally Despite Brent Nearing USD44

LONDON MARKET MIDDAY: Stocks Consolidate Gains After Four-Day Rally

BROKER RATINGS SUMMARY: Panmure Raises RSA Insurance To Buy From Hold

WINNERS & LOSERS SUMMARY: Upbeat Bellway Lifts Housebuilding Stocks

BROKER RATINGS SUMMARY: S&P And Shore Upgrade Aviva After Strong Half

LONDON MARKET OPEN: RBS Misses Gains After Swinging To Operating Loss

LONDON MARKET CLOSE: BoE Stimuli Push Up Stocks But Depress Sterling